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CARDIOPULMONARY BYPASS, MYOCARDIAL 
MANAGEMENT, AND SUPPORT TECHNIQUES 
CONSTITUTIVE NITRIC 
OXIDE RELEASE IS 
IMPAIRED AFTER ISCHEMIA 
AND REPERFUSION 
Myocardial ischemia nd reperfusion may result in endothelial dysfunction 
and reduced release of nitric oxide. With the use of an amperometric 
sensor, the first direct measurements of constitutive nitric oxide release 
from a beating heart were measured from the coronary effluent of isolated 
working rat hearts subjected to ischemia nd reperfusion. Rats, six to eight 
per group, were randomly studied as follows: control (no pretreatment) and 
pretreatment with the nitric oxide donor L-arginine (3 mmol/L), its 
enantiomer D-arginine (3 mmol/L), nitric oxide inhibitor N~-nitro-L-  
arginine methyl ester (100 /.tmol/L), and combined Nm--nitro-L-arginine 
methyl ester/L-arginine. Isolated hearts were pretreated for 10 minutes 
before 30 minutes of global ischemia and 30 minutes of reperfusion. A
nonischemic control group (n = 4) was continuously perfused with oxygen- 
ated unsupplemented buffer. After ischemia/reperfusion, hearts supple- 
mented with L-arginine recovered significantly (p < 0.05) increased 
developed pressure, first derivative of the aortic pressure (dP/dtmax) , and 
aortic flow compared with all other hearts that underwent ischemia/ 
reperfusion. In addition, nitric oxide release was significantly (p < 0.05) 
increased uring reperfusion in the L-arginine group. During reperfusion, 
the recovery of aortic flow correlated with nitric oxide release (r = 0.81,p < 
0.0001). We conclude that after ischemia/reperfusion, e dothelial dysfunc- 
tion results in decreased nitric oxide release, which can be ameliorated with 
L-arginine pretreatment. The direct cytoprotective properties of nitric 
oxide may contribute to improved functional recovery in hearts pretreated 
with L-arginine. Augmentation of the L-arginine/nitric oxide pathway may 
provide a new approach for improved recovery after cardiovascular oper- 
ations. (J THORAC CARDIOVASC SURG 1995;110:1047-53) 
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E ndothelium-derived relaxing factor is a naturally occurring, continuously released, vasoactive 
agent that controls coronary vascular tone. 1 Endo- 
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thel ium-derived relaxing factor, synonymous with 
nitric oxide (NO), is synthesized by the vascular 
endothelium through the conversion of L-arginine 
to L-citrulline by the enzyme NO synthase. 2' 3 En- 
dothelial cells produce NO in response to a wide 
range of agonists, including norepinephrine, adeno- 
sine diphosphate, calcium ionophore, acetylcholine, 
and bradykinin. 4 NO synthesis can be inhibited by 
the selective inhibitor NoJ-nitro-I.-arginine methyl 
ester (L-NAME). 5 Indirect methods for monitoring 
NO generation, with the use of isolated coronary 
arteries and veins, have documented impaired endo- 
thelium-dependent vasorelaxation (a measure of NO 
synthesis) after myocardial ischemia and reperfu- 
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Fig. 1. Schemata of experimental protocol for nonischemic ontrol hearts (NCON), ischemic control 
hearts (CON), and experimental hearts pretreated with L-arginine, n-arginine, and L-NAME. Myocardial 
function (dP/dtma ~, developed pressure, aortic flow, coronary flow, and heart rate) were measured at 
baseline and at 20 and 30 minutes of reperfusion. NO levels were measured uring working perfusion 
(W-P) at baseline and during 10 to 30 minutes of reperfusion. L-P, Langendorff perfusion. 
sion.6, 7 Further, reduced vasorelaxation can be atten- 
uated, and myocardial injury thereby reduced, with 
supplemental L-arginine. 8'9 However, in these models, 
the presence of NO has only been inferred on the 
basis of the physiologic effects of NO generation/ 
inhibition, and misleading information may there- 
fore be providedJ  °
With the use of a porphyrinic sensor, it has recently 
been demonstrated by direct measurements that the 
stimulated release of NO is impaired after myocardial 
ischemia associated with heterotopic rat heart trans- 
plantationJ 1 Because of the ubiquitous nature of NO, 
to our knowledge, the direct measurement of contin- 
uous basal NO release from beating hearts has not 
previously been reported. In this experiment an am- 
perometric probe was used to monitor continuous 
constitutive NO release from a working heart. We 
hypothesized that after global ischemia and reperfu- 
sion, coronary vascular endothelial cell dysfunction 
would result in reduced constitutive NO release, and 
that this could be ameliorated by the administration of
L-arginine before ischemia. We further examined the 
ability of L-arginine to preserve myocardial function 
after ischemia nd reperfusion. 
Material and methods 
Perfusion technique. Male Sprague-Dawley rats 
weighing 320 to 360 gm were anesthetized with an intra- 
peritoneal injection of sodium pentobarbital (Nembutal 
80 mg/kg) and with heparin (500 IU/kg) intravenously. All 
animals received humane care in compliance with the 
"Principles of Laboratory Animal Care" formulated by 
the National Society for Medical Research and the 
"Guide for the Care and Use of Laboratory Animals" 
prepared by the Institute of Laboratory Animal Resources 
and published by the National Institutes of Health (NIH 
Publication No. 86-23, revised 1985). After thoracotomy, 
the hearts were excised and placed in ice-cold perfusion 
buffer. The aorta was then cannulated and the hearts were 
perfused by the Langendorff method at a constant perfu- 
sion pressure of 100 cm of waterJ 2 
The perfusion medium consisted of a modified Krebs- 
Henseleit bicarbonate buffer (KHB) (millimolar concen- 
tration: NaC1 118, NaHCO3 24, KC1 4.7, KHaPO 4 1.2, 
MgSOa 1.2, CaC12 1.7, and glucose 10) gassed with 95% 
02/5% CO2 with a pH of 7.4 at 37 ° C. This solution was 
filtered through a 5 /xm filter to remove any particulate 
contaminants. The pulmonary vein was then cannulated 
and the Langendorff perfusion discontinued. The prepa- 
ration was then converted to the working heart mode, 
which is a preparation ofthe left side of the heart in which 
oxygenated KHB at 37 ° C enters the cannulated pulmo- 
nary vein and left atrium at a filling pressure of 17 cm 
H20. The perfusion fluid then passes to the left ventricle, 
from which it is ejected spontaneously through the aortic 
cannula against a pressure of 100 cm H20. Thus in this 
mode contractility and amounts of aortic and coronary 
flow could be measured. 13
Experimental design. The experimental protocol is 
shown in Fig. 1. All hearts were on the perfusion appara- 
tus for a total of 75 minutes. After conversion to the 
working heart mode, the hearts (n = 36) were perfused 
for 5 minutes with KHB. Baseline contractile function was 
then measured. The nonischemic control group (NCON; 
n = 4) then had continuous Langendorff perfusion for 50 
minutes followed by a 20-minute period of working per- 
fusion. The other groups had Langendorff perfusion for 10 
minutes with untreated KHB (ischemic ontrol group), 
KHB supplemented with L-arginine 3 mmol/L (Sigma 
Chemical Co., St. Louis, Mo.), its enantiomer, o-arginine 
3 mmol/L (Sigma), L-NAME 100 /~m/L (Sigma), or 
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L-NAME 100 /zm/L plus L-arginine 3 mmol/L. Normo- 
thermic global ischemia was then instituted by clamping 
the aortic and atrial cannulas. The animals were randomly 
assigned into groups as follows: ischemic ontrol (CON; 
n = 8), L-arginine plus ischemia (L-ARG; n = 6), 
D-arginine plus ischemia (D-ARG; n = 6), L-NAME plus 
ischemia (L-NAME; n = 6), and L-NAME/L-arginine 
plus ischemia (I.-ARG/L-NAME; n = 6). After 30 min- 
utes of global ischemia, hearts were reperfused with 
oxygenated KHB at 37 ° C via the Langendorff method for 
10 minutes, then converted to the working mode for 20 
minutes. Contractile function values were obtained after 
10 and 20 minutes of working heart reperfusion. 
NO measurement. NO release was measured continu- 
ously during working perfusion with the use of an ampero- 
metric sensor (ISO-NO, World Precision Instrument, 
Inc., Sarasota, Fla.). This probe measures the concentra- 
tion of NO gas in aqueous olution. 14 In brief, NO diffuses 
through a semipermeable membrane and is then oxidized 
at a working platinum electrode resulting in an electric 
current. This redox current is proportional to the concen- 
tration of NO at the membrane's outer surface. Electrode 
calibration was done daily before each experiment. A
calibration curve was obtained by measurement of the 
current generated by the addition of liquid nitrite 
(NaNO2; Curtin Matheson Scientific, Inc., Wilmington, 
Mass.) to a solution containing KI, H2504, and K2SO4. 
This resulted in the immediate generation of NO by the 
following equation: 
2NaNO2 + 2KI + 2H2SO 4 + 2K2SO 4 ~ 2NO 
+ I2 + 2H20 + 3KzSO4 + Na2SO4 
A typical calibration curve is seen in Fig. 2. NO calibration 
was always linear (r -> 0.99). After heart isolation and 
initiation of working perfusion, the NO probe was placed 
into the right atrial chamber to continuously measure NO 
in the coronary effluent. NO was measured only while the 
hearts were in the working mode (before and after 
ischemia) to eliminate potential flow differences between 
working and Langendorff perfusion. 
Indices of myocardial function. The aortic flow rate 
was measured by a calibrated rotameter and the coronary 
flow rate was measured by timed collection of the coro- 
nary effluent. Direct measurements of heart rate, devel- 
oped pressure (defined as the aortic end-systolic pressure 
minus aortic end-diastolic pressure), and the first deriv- 
ative of the aortic pressure (dP/dtmax) were made at each 
time. All data were recorded and analyzed in real time 
with the Cordat II data acquisition, analysis, and presen- 
tation system (Data Integrated Scientific Systems, Pinck- 
ney, Mich.; Triton Technologies, Inc., San Diego, Calif.). 
At the conclusion of the experiment all hearts were 
weighed. NO release was calculated in nanomoles per liter 
per gram wet weight. 
Statistical analysis. The values for myocardial function 
and NO release are expressed as the mean plus or minus 
the standard error of the mean. A two-way analysis of 
variance (Scheffe's) was first done to test for any differ- 
ences between groups. If differences were established, the 
values were compared by a Student's t test for paired data. 
Significance was considered at a p value < 0.05. Spear- 
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Fig. 2. Representative r lationship between NO concen- 
tration and output current of electrode (linear regression 
analysis). 
man's correlation coefficient was used to correlate NO 
release with the percent recovery of aortic flow. 
Results 
Myocardial  function. For the combined groups, 
baseline dP/dtmax, was 3099.8 +-- 65.4 mm Hg/sec, 
baseline developed pressure was 72.5 __- 0.9 mm 
Hg, baseline aortic flow rate was 44.5 _ 0.8 ml/min, 
and baseline coronary flow rate was 25.2 _ 0.5 
ml/min. There were no significant differences be- 
tween groups for any of these baseline values. The 
effect of  ischemia and reperfusion on myocardial 
contractile function measured at the end of 30 
minutes of reperfusion is shown in Table I. There 
was no significant difference between 20 and 30 
minutes of reperfusion for any of the hemodynamic 
variables in any group; data are therefore presented 
only for the 30-minute reperfusion measurement.  
After 30 minutes of  global ischemia and 30 minutes 
of reperfusion, the recovery of  dP/dtma~, developed 
pressure, and aortic flow was significantly increased 
in the L -ARC group compared with respective 
values in all other groups. The developed pressure 
in the L -NAME group was significantly decreased 
compared with that in all other groups. The addition 
of L-arginine to L -NAME produced an increased 
aortic flow rate compared with that in the L -NAME 
group; however, the rate remained significantly be- 
low that in the L -ARC group. The coronary flow 
rate was significantly decreased in the L -NAME 
group compared with that in the L -ARG group. The 
nonischemic ontrol hearts had a slight insignificant 
decrease from baseline values. Baseline heart rate 
was 313.0 ___ 0.5 beats/min. There was no difference 
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Table I. Hemodynamic data* and NO release? after 30 minutes of reperfusion 
Change in NO release 
Group %dP/dtma:¢ %DP %AF %CF (nmol/L/gm wet wO 
NCON (n = 4) 99 _+ 0.1 100 _-2- 2 93 4- 1 10l 4- 1 -11  4- 10 
CON (n = 8) 54 4- 4 51 _+ 2 21 _+ 3 74 _+ 5 -129  _-2 11 
L -ARG (n = 6) 77 4- 4:~ 75 4- 6:) 43 4- 4:) 86 + 3§§ -8  4- 11:) 
D-ARG (n = 6) 58 4- 7 55 4- 4 20 4- 6 73 4- 9 -119  4- 13 
L -NAME 100/xmol /L  (n = 6) 53 4- 4 41 _+ 311 15 ___ 3 66 -+ 4 -133  _+ 3 
L -ARG/L-NAME (n = 6) 57 4- 4 53 4- 3 23 4- 2§§ 72 4- 2 -114  4- 6§§ 
All data are expressed as mean plus or minus the standard error of the mean. dP/dtm,~ First derivative of aortic pressure; DP, developed pressure; AF, aortic 
flow; CF, coronary flow. 
*Hemodynamic data are percent recovery from baseline values. 
?NO release is reported as the change from baseline value 
:~ < 0.05 versus CON, D-ARG, L-NAME, L-ARG/L-NAME. 
§§p < 0.05 versus e-NAME. 
lip < 0.05 versus CON, L-ARG, D-ARG, L-ARG/L-NAME. 
in heart rate between any of the groups, at any point. 
Therefore ventricular pacing was not necessary for 
measurements of ventricular contractility. 
NO release. Baseline levels of NO from the right 
atrial chamber varied broadly with a mean value of 
263 _+ 17 nmol/L. Therefore results are reported as 
the change in NO release from baseline. NO values 
are reported as nanomoles per liter per gram wet 
weight (molarity per gram of heart issue) measured 
at a set time in the right atrial chamber. The 
concentration f NO in the right atrium is indepen- 
dent of coronary flow because the effluent is able to 
freely drain from this compartment. Regardless, in 
this study there were no statistical intergroup differ- 
ences in coronary flow among the L-ARG, D-ARG, 
or CON groups. In addition, there were no differ- 
ences in the postischemic wet weights among 
groups. The time course of NO release during 
working reperfusion is seen in Fig. 3. In early 
reperfusion, the L-ARG/L-NAME group had a sig- 
nificantly increased NO release compared with that 
in the D-ARG, L-NAME, and CON groups. How- 
ever, NO release rapidly declined in this group by 30 
minutes of reperfusion such that only the L-ARG 
group had near baseline values for NO release after 
30 minutes of reperfusion. 
The steady-state NO release after 30 minutes of 
reperfusion is seen in Table I. NO release was signif- 
icantly decreased from baseline values in all groups 
except he L-ARG group. Likewise, the nonischemic 
control group had a slight, but insignificant, decrease 
in NO release. In the combined group of all hearts that 
underwent ischemia nd reperfusion, the recovery of 
aortic flow correlated with NO release (r = 0.81, p < 
0.0001) as shown in Fig. 4. 
Discussion 
Researchers have been limited in their investiga- 
tion of NO, because of its scant release and rapid 
breakdown/consumption in biologic systems. 15 In 
this study, for the first time, we have directly mea- 
sured continuous constitutive or basal NO release 
from a working heart with the use of an extremely 
sensitive and specific NO probe. 14 Free NO has a 
half-life of 3 to 5 seconds in physiologic salt solu- 
tion, which makes its direct measurement di ficult. 4
We placed our NO probe into the right atrial 
chamber of beating hearts to measure newly gener- 
ated NO from the coronary sinus. We have demon- 
strated that during ischemia/reperfusion, constitu- 
tive NO release and myocardial contractility are 
decreased proportionally and do not return to base- 
line levels after 30 minutes of reperfusion. 
Ambient L-arginine levels have been shown to 
regulate NO synthesis/release. 14 Therefore, in the 
CON group, reduced intracellular L-arginine con- 
tent after ischemia/reperfusion may be responsible 
for reduced NO release. Other possibilities include 
impaired endothelial membrane receptors, de- 
creased L-arginine utilization, reduced NO synthase 
activity, reduced transport/release, or increased 
binding/degradation of NO. 16 Specifically, it has 
been suggested that the NO pathway fails after 
ischemia/reperfusion because of increased binding 
and breakdown by superoxide anion TM 17 and high 
shear stress and pressure on the coronary endothe- 
lium during reperfusion of ischemic myocardium) s 
It is logical to assume that ischemia/reperfusion 
adversely affects both endothelial cells and cardiac 
musculature. However, it is unclear whether de- 
creased NO release is partially responsible for de- 
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Fig. 3. Time course of NO release during working reper- 
fusion (n = 6 to 8 per group). Data are given as mean 
change from baseline values plus or minus tandard error 
of mean. *p < 0.05 versus all other groups; #p < 0.05 
versus o-ARG, CON, and L-NAME groups. 
creased myocardial function in this setting. In this 
study, we demonstrated that the degree of postisch- 
emic contractile dysfunction correlated with the 
degree of endothelial dysfunction. We have shown 
that e-arginine pretreatment resulted in significantly 
increased constitutive NO synthesis/release (tobase- 
line levels) and improved functional recovery after 
ischemia/reperfusion. This response was both spe- 
cific and stereoselective, inasmuch as D-arginine 
administration did not prevent the reduction i  NO re- 
lease or improve myocardial function on reperfusion. 
The maintenance of constitutive NO release ap- 
pears to be important in the recovery of function 
after an ischemic injury. Others have similarly dem- 
onstrated reduced infarct size 8' a9 and decreased 
contractile dysfunction 2° by supplementing NO re- 
lease after ischemia/reperfusion. We have shown 
that endogenous NO production can be readily 
augmented by providing excess L-arginine substrate 
before ischemia without being limited by impaired 
substrate uptake, synthesis, or release. It is impor- 
tant to note that exogenous NO donors were not 
necessary to maintain adequate NO release. Fur- 
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relatively resistant to the deleterious effects of isch- 
emia/reperfusion in this setting. 
We have confirmed the ability of L-NAME, an 
L-arginine analog, to block NO synthase, as evi- 
denced by reduced NO release in the L-ARG/L- 
NAME group compared with that in the L-ARG 
group. The fact that L-NAME pretreatment alone 
did not further reduce NO release compared with 
control values suggests that endothelial function is 
already at nadir levels. The antagonism ofL-NAME 
can reportedly be overcome by exogenous L-argin- 
ine. 2l This may explain the significantly increased 
NO release (especially in early reperfusion) seen in 
the L-ARG/L-NAME group compared with that in 
the L-NAME group. In addition, contractility was 
also slightly improved in the L-ARG/L-NAME 
group (as evidenced by significantly increased aortic 
flow) compared with that in the L-NAME group. 
This would suggest hat our dosage of L-arginine 
was able to partially overcome the antagonistic 
effect of L-NAME. 
The mechanism by which L-arginine pretreatment 
improved functional recovery after ischemia/reper- 
fusion is not clear. Coronary vasodilation was not a 
major component in this protection, because coro- 
nary flow was not significantly increased in hearts 
pretreated with e-arginine versus control hearts and 
collateral flow is not significant in the rat heart 
model. The systemic effects of L-arginine were also 
not a factor, inasmuch as the experiment was done 
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on isolated hearts. Others have shown that NO may 
be cardioprotective by inhibiting neutrophil aggre- 
gation and adherence. 22 This is clearly not a factor 
in the crystalloid-perfused rat heart model. 
Recent evidence has suggested that NO may 
directly protect against cellular damage from reac- 
tive oxygen species generated uring ischemia/ 
reperfusion by blocking the formation of hydroxyl 
radicals and terminating free radical chain reactions 
within the lipid membrane. 23 Further, it has been 
shown that nitroxides may be cytoprotective through 
the neutralization of oxygen-derived free radi- 
cals. 24'25 By binding and eliminating these toxic 
metabolites, NO may reduce lipid peroxidation and 
retard the damaging effects of reperfusion injury. 
This may explain why others have noted that the 
coronary vascular endothelium exhibits little dam- 
age immediately after ischemia, but that tremen- 
dous dysfunction appears after only 2.5 minutes of 
reperfusion.26, 27
Not all studies have concluded that NO supple- 
mentation is cardioprotective. Others have shown 
that NO augmentation may increase and NO syn- 
thase blockers may decrease postischemic injury. It 
has been suggested that increased peroxynitrite and 
hydroxyl radical formation may be cytotoxic. 2s' 29 
However, these results may be model dependent, 
with the predominance of data supporting the pro- 
tective ffects of NO supplementation. 
The ability to protect endothelial function before 
an ischemic insult may have direct clinical applica- 
bility. In our model, the maintenance of NO release 
at baseline levels after reperfusion was associated 
with significantly improved functional recovery. 
Similar findings might be expected in human sub- 
jects. It has recently been demonstrated in human 
beings that L-arginine supplementation i hibits 
platelet aggregation, 3° reduces neutrophil superox- 
ide anion release, 31 and normalizes coronary endo- 
thelial dysfunction. 32 This may be especially impor- 
tant after cardiac operations, because NO release 
has been found to be decreased in patients with 
coronary atherosclerosis 33 and diabetes. 34L-argin- 
ine supplementation to cardioplegic solutions may 
preserve ndothelial function during reperfusion. In
addition to its cytoprotective actions, enhanced NO 
release after cardiac operations may improve collat- 
eral circulation and reduce postoperative graft va- 
sospasm 35and thrombosis. 26
In conclusion, the continuous monitoring of 
constitutive NO release from working hearts has 
demonstrated that after ischemia/reperfusion NO
release is significantly decreased. Further, this de- 
crease was prevented by L-arginine pretreatment, 
which resulted in improved myocardial function on 
reperfusion. Although the exact mechanism or 
mechanisms for this protection remain unclear, NO 
appears to be an important component in the recov- 
ery of myocardium from an ischemic insult. 
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